Ambrx Biopharma (NYSE:AMAM – Get Rating) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Volatility and Risk
Ambrx Biopharma has a beta of -2.17, indicating that its share price is 317% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
Insider and Institutional Ownership
43.1% of Ambrx Biopharma shares are owned by institutional investors. Comparatively, 43.3% of Fennec Pharmaceuticals shares are owned by institutional investors. 5.1% of Ambrx Biopharma shares are owned by company insiders. Comparatively, 9.4% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for Ambrx Biopharma and Fennec Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ambrx Biopharma presently has a consensus target price of $4.00, indicating a potential upside of 108.33%. Fennec Pharmaceuticals has a consensus target price of $14.83, indicating a potential upside of 49.38%. Given Ambrx Biopharma’s higher probable upside, equities research analysts plainly believe Ambrx Biopharma is more favorable than Fennec Pharmaceuticals.
Earnings & Valuation
This table compares Ambrx Biopharma and Fennec Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ambrx Biopharma||$7.45 million||9.95||-$68.08 million||N/A||N/A|
|Fennec Pharmaceuticals||$170,000.00||1,539.79||-$17.35 million||($0.82)||-12.11|
Fennec Pharmaceuticals has lower revenue, but higher earnings than Ambrx Biopharma.
Fennec Pharmaceuticals beats Ambrx Biopharma on 7 of the 11 factors compared between the two stocks.
About Ambrx Biopharma
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.